

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following descriptions best represents the study design of the EXCALIBER-RRMM trial?
 - a. A Phase I/II study evaluating iberdomide/cyclophosphamide/dexamethasone for relapsed/refractory (R/R) multiple myeloma (MM)
 - b. A Phase I/II study evaluating mezigdomide/daratumumab/bortezomib/dexamethasone for newly diagnosed MM
 - c. A Phase III study evaluating iberdomide/daratumumab/dexamethasone versus daratumumab/bortezomib/dexamethasone for RR MM
 - d. A Phase III study evaluating mezigdomide/carfilzomib/dexamethasone versus pomalidomide/carfilzomib/dexamethasone for RR MM

2. Recently announced results of the EXCALIBER-RRMM study include which efficacy finding?
 - a. A numerical but nonsignificant improvement in minimal residual disease (MRD) negativity rates with the iberdomide-containing regimen
 - b. A statistically significant improvement in MRD negativity rates with the iberdomide-containing regimen
 - c. A numerical but nonsignificant improvement in overall survival (OS) with the iberdomide-containing regimen
 - d. A statistically significant improvement in OS with the iberdomide-containing regimen

3. Which of the following descriptions best represents the study design of the SUCCESSOR-2 trial?
 - a. A Phase I/II study evaluating iberdomide/cyclophosphamide/dexamethasone for RR MM
 - b. A Phase I/II study evaluating mezigdomide/daratumumab/bortezomib/dexamethasone for newly diagnosed MM
 - c. A Phase III study evaluating iberdomide/daratumumab/dexamethasone versus daratumumab/bortezomib/dexamethasone for RR MM
 - d. A Phase III study evaluating mezigdomide/carfilzomib/dexamethasone versus carfilzomib/dexamethasone for RR MM

4. The Phase III DETERMINATION 2 study is evaluating which of the following induction regimens for transplant-eligible patients with newly diagnosed MM?
 - a. Iberdomide/bortezomib/dexamethasone
 - b. Daratumumab/iberdomide/dexamethasone
 - c. Isatuximab/iberdomide/dexamethasone
 - d. Daratumumab/iberdomide/bortezomib/dexamethasone
 - e. Isatuximab/iberdomide/bortezomib/dexamethasone

5. The Phase II EMN26 study evaluating maintenance iberdomide after transplant for patients with newly diagnosed MM demonstrated which outcome in comparison to historical results with lenalidomide in the same setting?
 - a. A lower rate of improvement in response
 - b. A higher rate of improvement in response
 - c. An equivalent rate of improvement in response